AquacultureBronze report

Published April 2026Insight Research12 min read2026 Edition12 sources, 12 primary-gradeStrong source depth

Thailand Shrimp Disease & Biosecurity Deep Dive

EMS, WSSV drove Thai shrimp collapse from 600K+ to ~270K t. SPF broodstock, closed-system, probiotic feed, biosecurity audit are mitigations. Technical companion to Aquaculture overview.

Key takeaways

1
Thai farmed shrimp production collapsed from ~ tonnes (late-2000s peak) to ~ tonnes FY2024 — primarily driven by Early Mortality Syndrome (EMS / AHPND) caused by specific Vibrio parahaemolyticus strains, compounded by recurring White Spot Syndrome Virus (WSSV) outbreaks.
2
EMS mechanism: bacterial infection of the hepatopancreas in post-larvae shrimp; transmitted via water, broodstock, feed. WSSV is a DNA virus causing high mortality in adults. Other threats: Taura Syndrome Virus (TSV), Yellow Head Virus (YHV), Infectious Myonecrosis Virus (IMNV).
3
Mitigation stack: (1) SPF broodstock (Specific-Pathogen-Free breeding) from certified hatcheries; (2) closed-system / RAS (Recirculating Aquaculture System) farms; (3) probiotic, immunostimulant feed; (4) farm-level biosecurity, PCR testing, audit; (5) DOF-coordinated disease surveillance, rapid response.
4
Cost, adoption: SPF broodstock, closed-system, audited biosecurity are cost-constrained for smallholders (who supply ~ of Thai shrimp output). CPF, Thai Union captive farms, large commercial operators have higher adoption; certification (BAP, ASC) is the market-access driver.
5
Our read: disease resilience is the binding constraint on Thai shrimp recovery. SPF, biosecurity, closed-system are investable themes. Without material adoption increase, Thai shrimp loses more share to Indian, Indonesian, Vietnamese peers.

Executive summary

Thailand's shrimp industry has been shaped for over a decade by disease. Peak production of tonnes in the late-2000s collapsed dramatically from 2012 onwards driven by Early Mortality Syndrome (EMS / Acute Hepatopancreatic Necrosis Disease / AHPND), caused by specific Vibrio parahaemolyticus strains. White Spot Syndrome Virus (WSSV), Taura Syndrome Virus (TSV), and Yellow Head Virus (YHV) add recurring outbreak pressure. FY2024 production at ~ tonnes is approximately of peak; recovery has been partial, uneven, vulnerable to El Niño climate stress.^{[, , ]}

The mitigation stack has five layers. (1) SPF broodstock (Specific-Pathogen-Free breeding), biosecure hatchery operations — BIOTEC, private hatcheries have developed Thai SPF Penaeus vannamei lines with disease-resistance traits. (2) Closed-system / RAS (Recirculating Aquaculture System) farms — contain water, minimise disease vector entry; capital-intensive. (3) Probiotic, immunostimulant feed formulations — TFM, CPF, Grobest, specialist researchers. (4) Farm-level biosecurity, PCR testing, audit — BAP / ASC certification requirements. (5) DOF-coordinated disease surveillance, rapid-response containment.^{[, , , , ]}

Commercial economics: SPF broodstock, closed-system, audited biosecurity are cost-constrained for smallholders (supplying ~ of Thai shrimp output). Large commercial operators (CPF, Thai Union captive farms, commercial farms on BAP/ASC-certified pathways) have meaningfully higher adoption. EU/US retailers increasingly demand certified biosecure supply chains — the 'premium-certified vs commodity' market segmentation is widening. Indian, Indonesian, Vietnamese competitors have gained share partly on lower cost but also partly on aggressive SPF, biosecurity adoption.^{[, , ]}

DOF, BIOTEC, EMS/WSSV research, BAP/ASC, SCB EIC, TSA

Data as of: FY2024

Biosecurity mitigation stack (% of industry investment, focus, estimate)

SPF broodstock, hatchery biosecurity

Share %

30%

Notes

Disease-free genetic lines, certified hatcheries

Closed-system, RAS farms

Share %

20%

Notes

Recirculating water, vector isolation

Probiotic, immunostimulant feed

Share %

20%

Notes

TFM, CPF, Grobest formulations

Farm-level biosecurity, audit

Share %

20%

Notes

PCR testing, protocols, BAP/ASC audit

Disease surveillance, rapid response

Share %

10%

Notes

DOF, industry early-warning

Mitigation layer	Share %	Notes
SPF broodstock, hatchery biosecurity	30%	Disease-free genetic lines, certified hatcheries
Closed-system, RAS farms	20%	Recirculating water, vector isolation
Probiotic, immunostimulant feed	20%	TFM, CPF, Grobest formulations
Farm-level biosecurity, audit	20%	PCR testing, protocols, BAP/ASC audit
Disease surveillance, rapid response	10%	DOF, industry early-warning

BIOTEC, TSA, operator disclosures, SCB EIC

Data as of: FY2024

Analyst framing

Why this deep dive

Disease is the single structural constraint on Thai shrimp recovery. SPF, biosecurity, closed-system adoption, BAP/ASC certification are the investable, operator-adoption themes. Thai shrimp sector recovery depends on scaling these mitigations to smallholders.

Disease mechanism, mitigation playbook

EMS / AHPND (Early Mortality Syndrome / Acute Hepatopancreatic Necrosis Disease): bacterial disease caused by specific toxigenic strains of Vibrio parahaemolyticus. Affects post-larvae shrimp; mortality peaks 20-30 days post-stocking. Transmitted via water, broodstock (maternal), contaminated feed. Mitigation: SPF broodstock, PCR testing, probiotic feed, salinity/temperature management. WSSV (White Spot Syndrome Virus): DNA virus with broad host range; mortality up to 100% in affected ponds within days. Mitigation: strict water, equipment, staff biosecurity, rapid removal of infected ponds.

SPF broodstock: Thai hatcheries (including BIOTEC-linked research) have developed Specific-Pathogen-Free Penaeus vannamei lines — bred, tested to exclude EMS, WSSV, TSV, YHV, IMNV. Hatchery biosecurity (HEPA filtration, dedicated personnel, PCR screening) is critical. Closed-system / RAS (Recirculating Aquaculture System): contain water reuse, biosecurity; capital-intensive (THB 30-50M per module), requires skilled operations. Better-suited to medium-scale commercial farms than smallholders.

Probiotic, immunostimulant feed: TFM (Thai Union Feedmill), CPF's aquafeed division, Grobest, and specialist researchers have developed feed formulations with Bacillus, Lactobacillus, beta-glucan, nucleotide additives to strengthen shrimp immunity, gut microbiome against Vibrio pathogens. Farm biosecurity, BAP/ASC audit: PCR testing, quarantine, water treatment, staff hygiene, facility isolation. BAP 4-star, ASC certification increasingly required for EU/US retailers. DOF surveillance: national disease-reporting network, rapid-response teams for confirmed outbreaks.

Scenarios to 2031

Bull: SPF, RAS scale-up, disease control

~350K t recovery

SPF broodstock adoption reaches 80% of Thai hatcheries; RAS adoption doubles; probiotic feed mainstream; disease mortality halves; BAP/ASC penetration 60%+; Thai shrimp recovers share vs Indian, Indonesian peers.

Base case

~280K t

Incremental adoption; large commercial operators lead; smallholder gap persists; disease cycles oscillate; Thai shrimp holds current share.

Bear: disease persistence, climate

~220K t

El Niño, new disease variants overwhelm mitigations; smallholder exit accelerates; Thai shrimp loses further share; BAP/ASC certification fails to scale.

Unlock the full deep dive

Disease mechanism, mitigation playbooks, adoption economics, scenarios, recommended actions.

Unlock deep dive·$99

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Related reports

Thailand Aquaculture Market Intelligence

Thailand aquaculture spans farmed shrimp (~270K t/yr, declining on disease, weather), tilapia (domestic), seabass, marine fish, and pangasius. Report maps upstream economics — aquafeed (Thai Union Feedmill SET: TFM, CPF, Grobest), hatchery, broodstock, shrimp farming, disease cycles (EMS, WSSV), and the competitive dynamic with Indonesian, Vietnamese, Indian aquaculture peers. Complements the existing Seafood Processing & Export report which focuses on the downstream side.

Open report →

Thailand Seafood Processing & Export Market Intelligence

Thailand sold USD 7.14B of seafood to the rest of the world in 2024 — a 10-year high — and holds the world's largest canned-tuna position at roughly 35% global share. Market-access rules, not price, are the binding constraint. This report walks through the post-2015 IUU rebuild, the four listed processor playbooks (Thai Union, CPF, Surapon, Asian Sea Corp), US FDA, EU sustainability exposure, and a 5-year scenario band.

Open report →

Thailand AI Drug Discovery & Pharma-Biotech 2027 Market Intelligence

Thailand's pharma sector is pivoting from Big Pharma agency, GPO generics, and bulk-API import toward AI-driven drug discovery, repurposing, biomarker stratification, and Thai-population-specific compound screening, propelled by the Genome Thailand 50K WGS cohort, the USD 35M BIOTEC AI Drug Discovery Centre, BOI Section 8 R&D tax incentives, and a TFDA accelerated approval pathway for AI-discovered compounds. By 2027 the addressable Thai AI drug discovery and pharma biotech AI-tooling pool reaches THB 14-24B revenue (vs THB 1.4-2.4B 2024). The report maps activity mix, operator concentration across BIOTEC, Mahidol, Chula, Siriraj, GPO, Siam Bioscience, Bionet-Asia, and the Insilico, Atomwise, Exscientia, Iktos Thailand JVs, plus unit economics, regulation, and 2031 scenarios.

Open report →

Thailand BCG Bio-Circular Green Economy 2027 Market Intelligence

Thailand's Bio-Circular-Green (BCG) Economy is the country's flagship national industrial strategy, positioning the kingdom as ASEAN's premier biotech, circular-economy, low-carbon production hub. The framework spans four pillars: bio-agriculture (functional food, biopesticides, bio-stimulants), bioenergy (biofuel, biogas, biomass-to-power), biochemicals (lactic, succinic, levulinic acid plus PLA bioplastics), and bioproducts (cosmeceuticals, nutraceuticals, medical-grade). The 2027 catalyst stack is unusually dense: BOI Section 8 BCG Economy bonus (additional 5-year tax holiday plus 50% local-content procurement preference), Eastern Economic Corridor of Innovation (EECi) Wangchan Valley biopharma and biorefinery cluster ramping to 80% occupancy, NSTDA BIOTEC plus Mahidol and KMITL spin-out pipeline (three IPOs targeted by 2027), Coca-Cola, Unilever, Nestle, PepsiCo signing Thailand-sourced PLA, bio-PE, bio-PET offtake reaching USD 1.4-2.2B, the MOST plus MOC plus Industry Ministry Bio-Cluster Strategic Investment Fund (USD 1.5B 2025-2030), the EU-Thailand FTA Bio Annex (signed March 2026) granting Thai PLA, biochemicals 0% tariff into the EU versus 6.5% for China, and T-VER carbon-credit stacking adding 7-12% IRR to bioenergy projects. Base case: 2027 Thai BCG framework cluster gross output reaches USD 24-36B (vs USD 11-15B in 2024), with PTTGC, CPF, Mitr Phol, IVL, ThaiBev, NSTDA BIOTEC, and EECi capturing 70%-plus share. Long-tail of BCG-aligned biotech start-ups and SME bio-processors absorbs the remainder.

Open report →